Use of recombinant adenovirus vectored consensus IFN-α to avert severe arenavirus infection

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Gowen, Brian B ^a   Ennis, Jane ^b   Russell, Andrew ^a   Sefing, Eric J ^a   Wong, Min Hui ^a   Turner, Jeffrey ^b  

^a UTAH STATE UNIVERSITY   (United States)

^b Defyrus Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; PLACEBO; RECOMBINANT ALPHA INTERFERON; RECOMBINANT CONSENSUS ALPHA INTERFERON; UNCLASSIFIED DRUG; ALPHA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARENAVIRUS INFECTION; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MODEL; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HAMSTER; HOST RESISTANCE; LIVER DISEASE; MORTALITY; NONHUMAN; PICHINDE ARENAVIRUS; POST EXPOSURE PROPHYLAXIS; PRE EXPOSURE PROPHYLAXIS; PROPHYLAXIS; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM; VIRUS IMMUNITY; VIRUS REPLICATION; ADENOVIRUS; ANIMAL; GENE VECTOR; GENETIC RECOMBINATION; GENETICS; SYRIAN HAMSTER;

ADENOVIRIDAE; ANIMALIA; ARENAVIRUS; CRICETINAE; PICHINDE VIRUS;

ADENOVIRIDAE; ANIMALS; ARENAVIRIDAE INFECTIONS; CRICETINAE; FEMALE; GENETIC VECTORS; INTERFERON-ALPHA; MESOCRICETUS; RECOMBINATION, GENETIC;

EID: 80055061478     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026072     Document Type: Article

References (34)

1. Paweska JT, Sewlall NH, Ksiazek TG, Blumberg LH, Hale MJ, et al. (2009) Nosocomial outbreak of novel arenavirus infection, southern Africa. Emerging infectious diseases 15: 1598-1602.
2. Enria DA, Briggiler AM, Sanchez Z, (2008) Treatment of Argentine hemorrhagic fever. Antiviral Res 78: 132-139.
3. Khan SH, Goba A, Chu M, Roth C, Healing T, et al. (2008) New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res 78: 103-115.
4. de Manzione N, Salas RA, Paredes H, Godoy O, Rojas L, et al. (1998) Venezuelan hemorrhagic fever: clinical and epidemiological studies of 165 cases. Clin Infect Dis 26: 308-313.
5. Buchmeier M, Bowen MD, Peters CJ, (2001) Arenaviridae: The viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, editors. Fields Virology Fourth ed. Philadelphia Lippincott Williams & Wilkins pp. 1635-1638.
6. CDC website. Available: http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/lassaf.htm. Accessed 2011, October 4.
7. NIAID, eds. (2002) The Counter-Bioterrorism Research Agenda of the National Institute of Allergy and Infectious Diseases (NIAID) for CDC Category A Agents. Bethesda.
8. Maiztegui JI, Fernandez NJ, de Damilano AJ, (1979) Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 2: 1216-1217.
9. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, et al. (1986) Lassa fever. Effective therapy with ribavirin. New England Journal of Medicine 314: 20-26.
10. Bausch DG, Hadi CM, Khan SH, Lertora JJ, (2010) Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis 51: 1435-1441.
11. Hadi CM, Goba A, Khan SH, Bangura J, Sankoh M, et al. (2010) Ribavirin for Lassa fever postexposure prophylaxis. Emerg Infect Dis 16: 2009-2011.
12. Barry M, Russi M, Armstrong L, Geller D, Tesh R, et al. (1995) Brief report: treatment of a laboratory-acquired Sabia virus infection. N Engl J Med 333: 294-296.
13. Kilgore PE, Ksiazek TG, Rollin PE, Mills JN, Villagra MR, et al. (1997) Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clinical Infectious Diseases 24: 718-722.
14. Brassard DL, Grace MJ, Bordens RW, (2002) Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 71: 565-581.
15. Gowen BB, Barnard DL, Smee DF, Wong MH, Pace AM, et al. (2005) Interferon alfacon-1 protects hamsters from lethal pichinde virus infection. Antimicrob Agents Chemother 49: 2378-2386.
16. Gowen BB, Smee DF, Wong MH, Pace AM, Jung KH, et al. (2006) Combinatorial ribavirin and interferon alfacon-1 therapy of acute arenaviral disease in hamsters. Antivir Chem Chemother 17: 175-183.
17. Gowen BB, Holbrook MR, (2008) Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. Antiviral Res 78: 79-90.
18. Bell SJ, Fam CM, Chlipala EA, Carlson SJ, Lee JI, et al. (2008) Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic. Bioconjug Chem 19: 299-305.
19. Julander JG, Ennis J, Turner J, Morrey JD, (2011) Treatment of Yellow Fever Virus with an Adenovirus-Vectored Interferon, DEF201, in a Hamster Model. Antimicrobial agents and chemotherapy 55: 2067-2073.
20. Wu JQ, Barabe ND, Huang YM, Rayner GA, Christopher ME, et al. (2007) Pre- and post-exposure protection against Western equine encephalitis virus after single inoculation with adenovirus vector expressing interferon alpha. Virology 369: 206-213.
21. Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, et al. (2008) Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PloS one 3: e3548.
22. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, et al. (2007) In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 51: 3168-3176.
23. Reed LJ, Muench H, (1938) A simple method of estimating fifty percent endpoints. American Journal of Hygiene 27: 493-497.
24. Shayakhmetov DM, Di Paolo NC, Mossman KL, (2010) Recognition of virus infection and innate host responses to viral gene therapy vectors. Molecular therapy: the journal of the American Society of Gene Therapy 18: 1422-1429.
25. Pannetier D, Faure C, Georges-Courbot MC, Deubel V, Baize S, (2004) Human macrophages, but not dendritic cells, are activated and produce alpha/beta interferons in response to Mopeia virus infection. Journal of virology 78: 10516-10524.
26. Martinez-Sobrido L, Giannakas P, Cubitt B, Garcia-Sastre A, de la Torre JC, (2007) Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J Virol 81: 12696-12703.
27. Marq JB, Hausmann S, Veillard N, Kolakofsky D, Garcin D, (2011) Short double-stranded RNAs with an overhanging 5′ ppp-nucleotide, as found in arenavirus genomes, act as RIG-I decoys. The Journal of biological chemistry 286: 6108-6116.
28. Fan L, Briese T, Lipkin WI, (2010) Z proteins of New World arenaviruses bind RIG-I and interfere with type I interferon induction. Journal of virology 84: 1785-1791.
29. Martinez-Sobrido L, Zuniga EI, Rosario D, Garcia-Sastre A, de la Torre JC, (2006) Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. Journal of virology 80: 9192-9199.
30. Baize S, Marianneau P, Loth P, Reynard S, Journeaux A, et al. (2009) Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. Journal of virology 83: 5890-5903.
31. Garcia-Sastre A, Biron CA, (2006) Type 1 interferons and the virus-host relationship: a lesson in detente. Science 312: 879-882.
32. Kumaki Y, Ennis J, Rahbar R, Turner JD, Wandersee MK, et al. (2011) Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model. Antiviral research 89: 75-82.
33. O'Brien L, Perkins S, Williams A, Eastaugh L, Phelps A, et al. (2009) Alpha interferon as an adenovirus-vectored vaccine adjuvant and antiviral in Venezuelan equine encephalitis virus infection. J Gen Virol 90: 874-882.
34. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, et al. (2007) Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. Journal of virology 81: 4654-4663.